By the Top Tier Newswire AI Desk · November 20, 2026 at 9:42 AM ET · reviewed against 9 wire stories
SAVARA INC (SVRA) is down -18.39% in the latest session. Our newswire has captured 9 stories on SVRA across 7 sources in the last 36 hours, with AI sentiment reading bearish (avg 29/100).
Public view, delayed 4h. Every headline, price and sentiment read below — and this write-up itself — reaches Pro subscribers live. Public readers see it once it clears the delay.
Savara Inc (SVRA) shares fell 16.89% to $4.33 following a regulatory setback regarding its lead drug candidate. The decline was driven by the US Food and Drug Administration's decision not to take action on the Biologics License Application for molgramostim by the scheduled Prescription Drug User Fee Act target date.
What Happened
Savara announced that the FDA will not meet the PDUFA target action date for the molgramostim BLA for Autoimmune Pulmonary Alveolar Proteinosis. This regulatory update represents a significant delay for the company’s primary commercial asset. The news triggered an immediate sell-off, with the stock opening at $5.28, a 1.2% gap up from the prior close of $5.21. However, the sentiment reversed sharply during the morning session, with the price dropping to a low of $3.10 by 8:30 AM ET before stabilizing near the close.
What The Data Shows
Trading volume reached 3.8 million shares, which is 1.7 times the three-month daily average, indicating heightened institutional and retail activity in response to the news. The stock's beta of 0.30 suggests low correlation to the broader market, yet the move was driven entirely by company-specific regulatory news. Savara remains unprofitable with a trailing twelve-month earnings per share of negative $0.61 and a market capitalization of $1.3 billion. The intraday low of $3.10 briefly pushed the stock below its 52-week low of $4.13, marking a fresh low on November 20, 2026. This volatility contrasts with the prior eight sessions, where the stock had gained 5.9% from $4.92 to $5.21. Retail sentiment has deteriorated, with the seven-day average sentiment score dropping to 45 from a 30-day average of 51.
What To Watch
Investors will monitor for a new PDUFA date or further regulatory guidance from the FDA regarding the molgramostim application. The company recently presented new clinical data for molgramostim in aPAP patients and provided an update on its UK Marketing Authorization Application submission, which may offer additional context on the regulatory pathway.
AI-assisted analysis composed exclusively from headlines and data on the Top Tier newswire. Public view is delayed 4 hours from real time. Not financial advice.
SVRA · Nov 20 session (5-min) · -16.72% vs prior close · updated 3:39 PM ETAI sentiment, last 36h · averaged over 9 stories · 29/100 bearish
The headlines behind the move
Story flow · 9 stories on the wire, last 36h · hover or tap a dot for the headline
1d agoGuruFocusBEARISH 38Analyst
SVRA Maintained by HC Wainwright & Co. -- Price Target Lowered to $9.00
1d agoGuruFocusBEARISH 22General
FDA Delay on Molgramostim Review Sends Savara (SVRA) Shares Down 18%
1d agoMarketWatchBEARISH 22General
Savara Shares Tumble, FDA to Miss Target Date for License of Lung Disease Treatment
1d agoThe FlyBEARISH 42Analyst
Savara price target lowered to $9 from $10 at H.C. Wainwright
1d agoSeeking AlphaBEARISH 22General
Savara drops after FDA says it will not meet molgramostim BLA action date
Savara shares fall about 18% after the FDA says it will miss the Nov. 22 PDUFA date for molgramostim. Read more here.
1d agoStocktwits NewsBEARISH 22General
SVRA Stock Hits 52-Week Low After FDA Delays Decision On Lung Disease Drug Application
Savara said the FDA’s review of Molgramostim is ongoing, but did not provide a revised date for the decision.
1d agoInvesting.com MarketsBEARISH 22General
Why is Savara stock plunging today?
Why is Savara stock plunging today?
1d agoThe FlyBEARISH 35General
Savara says US FDA will not meet PDUFA target action date for molgramostim BLA
1d agoStockTitanBEARISH 32General
Savara Informed That FDA Will Not Take Action on the Molgramostim BLA for Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP) by the PDUFA Date
Frequently asked questions
Why is SVRA stock down today?
SAVARA INC (SVRA) is down -18.39% in the latest session. Our newswire has captured 9 stories on SVRA across 7 sources in the last 36 hours, with AI sentiment reading bearish (avg 29/100). The most recent driver: "SVRA Maintained by HC Wainwright & Co. -- Price Target Lowered to $9.00" (GuruFocus).
Is SVRA a buy right now?
Top Tier Newswire does not give financial advice. Our AI sentiment across the last 36 hours of SVRA coverage reads 29/100 over 9 stories; treat it as a research signal and do your own diligence.
How fast does this page update?
The data sections refresh continuously as the newswire lands coverage; the written analysis is published once per trading day. Pro subscribers additionally get real-time push alerts, watchlists, and the full live terminal.
Want the next move before the crowd? The live terminal streams every headline in real time with watchlist alerts, AI sentiment, and the full data stack behind this page.Get Pro Access →